Rapid Novor Inc. Launches REmAb™ Antibody Protein Sequencing Services on Science Exchange

January 24, 2018 | Posted by Team in News |

PALO ALTO, CA, January 25, 2018 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced a partnership with Rapid Novor Inc to offer its REmAb™ Antibody Protein Sequencing Services to scientists around the world using Science Exchange’s R&D platform.

Rapid Novor, Inc. is a Kitchener-Waterloo (Canada)-based CRO dedicated to the development of antibody protein sequencing technologies. The company’s mission is to advance life science research to better human health with next-generation protein sequencing. With the opening of its own state-of-the-art mass spectrometry lab in 2017, the team has successfully sequenced hundreds of monoclonal antibodies directly from the proteins and helped pharmaceutical companies in their antibody drug discovery.

“Our focus is on the development of antibody protein sequencing technologies, and we are the only team that has both a mass spectrometry lab and proprietary sequencing software platform,” said Mingjie Xie, Co-founder and CEO of Rapid Novor, Inc. “We are uniquely positioned to offer superior protein sequencing services to researchers worldwide. The partnership with Science Exchange will allow us to provide easy-to-access services to enterprise biopharma companies and offer them cutting-edge technologies in a seamless manner.”

“We are thrilled to partner with Rapid Novor Inc to make its REmAb™ Antibody Protein Sequencing Services available to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “By partnering with the leading CROs in different research and technology sectors, we are bringing in the best and brightest service providers to our secure and readily available platform so that the scientists can focus on developing breakthrough discoveries. Having Rapid Novor Inc as part of our supplier portfolios is an example of our commitment to making it easy for researchers to access the world’s leading scientific service providers and most innovative scientific technologies.”

About Rapid Novor, Inc.

Rapid Novor, Inc. is the world’s leader in antibody protein sequencing technology. Specializing in the field of mass spectrometry-based proteomics, the team has developed the technology to directly sequence the antibody proteins without needs to access the cell line. As a University of Waterloo spin-off, the company is building its technology portfolios based on the twenty years of scientific research and inventions from Dr. Bin Ma, co-founder and chief scientist. The company’s REmAb™ antibody protein sequencing service has allowed the accurate sequencing of any given antibody proteins routinely. The company’s WILD™ service is the first commercially available service that can accurately distinguish the isomeric isoleucine and leucine using mass spectrometry. For more information, visit www.rapidnovor.com. Follow the company on Twitter @rapidnovor.

Meet Service Providers with ADC (Antibody-Drug Conjugate) Expertise

March 22, 2017 | Posted by Diana Truong in Innovation Highlight |

Chemical structure of “emtansine” (mertansine plus linker) linked to a monoclonal antibody (maytansine black, mertansine modification red, linker blue.

The excitement around ADCs for treating cancer stems from the realization that traditional, small-molecule cytotoxic drugs and radiation are still some of the most potent anticancer agents, and that targeting them by tethering them to antibodies might bypass some of the side effects.

The recent founding investment by Johnson & Johnson of the ADC-focused startup, Fusion Pharmaceuticals, may provide some momentum to the development of targeted radiotherapeutics, a specific type of ADC. Johnson & Johnson’s investment followed on the heels of recent ADC investments by other large pharmas, including Boehringer Ingelheim and AstraZeneca. IMMU-132, the ADC being developed by Immunomedics, and SGN-LIV1A from Seattle Genetics are ADCs that are reported to target triple-negative breast cancer.

The biopharmaceutical industry currently has over two dozen ADC candidates estimated to be in its pipeline, indicating that there is a current demand for scientists with specific expertise in the techniques required for designing, synthesizing, and studying these molecules. In addition to developing expertise in-house, companies are frequently partnering with smaller companies or outsourcing projects to service providers to get the work done.

At Science Exchange, we have a unique bird’s-eye view of ADC-focused research and the service providers that are facilitating progress in this exciting field. Researchers who order services using the Science Exchange marketplace gain rapid access to an innovative network of 3,000+ service providers, including a number that supports ADC studies, through a single contract with Science Exchange. In this blog post, we’ll go through some of the key techniques and show how featured service providers in our network are meeting needs of ADC researchers.

Key techniques for studying ADCs: Science Exchange service providers step up.

Target discovery: the abundance challenge

Many ADC research programs seek to target cell surface proteins that are unique to the cell type that is to be killed by the cytotoxin. However, cell surface proteins, and other ADC targets, are usually low in abundance and underrepresented in traditional proteomic measurements.

One of the newest, cutting-edge providers on the Science Exchange network is Biognosys, offering discovery proteomics solutions based on Hyper Reaction Monitoring (HRM-MS™), a Next Generation proteomics technology. Invented at Biognosys, HRM-MS delivers quantification of up to 9’000 proteins per sample across treatments or conditions and identifies significantly regulated proteins. This platform is ideal for ADC target discovery studies, with one proof-of-concept study showing the quantification of over 500 cell surface proteins from matched biopsy samples.

The conjugation challenge

The ideal linker between the antibody and the cytotoxin drug is stable in the bloodstream, and if needed, can be cleaved in the specific environment of the target. Some ADC linkers are designed to dissolve the the reducing environment of the cytosol, while others require specific enzymes of certain subcellular compartments. Other linkers are non-cleavable. The linker also has to have minimal toxicity.

In addition to some wizardry in chemical synthesis, ADC development therefore requires experience in cell-based assays and drug metabolism studies. WuXi Apptec, MabPlex, and ChemPartner are service providers listed on the Science Exchange marketplace that have worked side by side with ADC developers on all aspects of linker synthesis and characterization.

Conjugation-related services that WuXi ApptecChemPartner and MabPlex provide include but are not limited to:

  • Cytotoxin development
  • Linker development
  • Linker and cytotoxin conjugations
  • Drug linking site determination
  • Stability studies for ADC products

 

Bioanalysis in ADC development: the heterogeneity challenge

Unlike other categories of drug molecules, ADCs can be structurally heterogeneous, because of dynamic drug:antibody ratios (DAR) and variations in linker attachment chemistry. In a recent survey, 69% of researchers cited this structural heterogeneity as the #1 challenge facing bioanalysis in ADC development.

85% of the surveyed researchers reported using LC-MS for ADC bioanalysis. However, over 24% respondents had to adapt traditional LC-MS methods, using affinity capture LC-MS or accelerator MS. 42% of respondents reported using ligand-binding assays, illustrating that most researchers use more than one technique in analyzing ADCs. The complexity of analytes, in combination with the lack of regulatory guidance around ADC analysis, have resulted in the need to use multiple, individually developed, methods.

Fortunately, the Science Exchange marketplace features the services of Biognosys, Anaquant, and ChemPartner, all of which provide experience in developing analytical methods for ADCs.

To address the challenge of quantifying multiple species per sample, Biognosys provides targeted proteomics services using Multiple and Parallel Reaction Monitoring (MRM and PRM), which are techniques that offer highly specific and sensitive multiplexed quantification of selected proteins from complex biological samples. These techniques deliver absolute or relative quantification of up to 150 target proteins per run with a dynamic range of 6 orders of magnitude.

Countless other service providers, such as Bio-Synthesis, Bionova, and Maine Biotechnology Services, are experts in analyzing ADCs using ligand-binding assays. In addition, Science Exchange’s in-house regulatory compliance team has expertise in working with representatives from regulatory agencies, to ensure that the analytical services carried out by our service providers meet necessary requirements.
ADC bioanalysis services on the Science Exchange marketplace include:

  • DAR (drug:antibody ratio) determination
  • Residual free drug analysis
  • Pharmacokinetics (PK) determination

 

Process development for ADC

Again, the heterogeneity of a batch of ADC can make it challenging to develop a scalable, reproducible, and robust manufacturing process. Manufacturing the antibody component of the ADC faces all the same challenges as does traditional therapeutic mAb production.

Given the demands of manufacturing, engineering quality by design is important in the nonclinical, preclinical and early clinical phases of ADC research. Expertise in antibody optimization, protein purification, and chemical synthesis are required to create less heterogeneous batches of antibodies, linkers, cytotoxins and conjugates.

Science Exchange service providers WuXi Apptec, MabPlex and ChemPartner all support ADC process development, with MabPlex’s services extending to GMP and scale-up (to kilogram scale).

Browse our marketplace for ADC-related services or contact our Concierge Service, who can match your project needs with the right service provider or a combination of service providers to move your ADC research forward.

About Science Exchange

We are transforming scientific collaboration by creating a marketplace where scientists can order experiments from the world's top labs.

Check the Science Exchange blog for updates, opinions, guest posts and the latest happenings at Science Exchange HQ!

Visit Science Exchange →

Subscribe to the blog
Never miss a post! Science Exchange blog posts delivered right to your inbox.
Thank you for joining the SciEx revolution!
Powered By WPFruits.com